PMS38 A Structured Literature Review of Rheumatoid Arthritis Economic Models for Biologics  by van Nooten, F. et al.
simulate RA evolution after treatment with etanercept (basecase treatment), ada-
limumab or infliximab as first-line therapies and their associated costs over a
12-month time horizon. Therapy continuation or switch was evaluated at week 24.
Effectiveness measures were ACR70 response and quality adjusted life years
(QALYs) gained. Direct medical costs included biologics, concomitant drugs, med-
ical follow-up and adverse events management. Clinical response was extracted
from published literature, while costs were collected from Colombian public offi-
cial databases. Probabilistic sensitivity analyses were performed through Monte
Carlo Simulation second-order approach. RESULTS: In base case analysis esti-
mated effectiveness resulted in [ACR70, QALY]: etanercept [31.3%, 0.79]; adali-
mumab [18.1%, 0.77] and infliximab [12.8%, 0.73]. Expected mean costs per patient
were 23,065USD, 24,869USD and 25,853USD, respectively. In cost-effectiveness and
cost-utility analysis, etanercept was the less costly and the most effective alterna-
tive being cost-saving in all comparisons: 2789USD less than infliximab(most costly
alternative); 18.5% more patients met ACR70 response regarding infliximab(the
least effective alternatives); incremental utility reached -0.0576 versus infliximab.
Acceptability curves showed that etanercept regardless willingness to pay would
be the most cost-effective biologic. CONCLUSIONS: Due to its lower costs and
favorable effectiveness profile, etanercept is dominant regarding ACR70 response
and QALYs gained over other biologic treatments in the management of RA at
Colombian public health care system.
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OBJECTIVES: Oral glucosamine formulations are frequently used as a food supple-
ment for joint maintenance, with little supportive evidence. However, Glusartel, a
formulation of glucosamine (produced by Rottapharm), has been shown to in-
crease oral bioavailability and has been studied in over 7,000 patients, showing a
significant improvement in joint space narrowing and knee replacement. The cost-
effectiveness of the new product was studied compared to both standard of care
and other glucosamine products. METHODS: A four state (with death as a sink
state) Markov model was constructed to investigate disease progression, patient
utility (mapped from the Western Ontario and McMaster Universities Arthritis
Index (WOMAC)) and cost. Efficacy was taken from two pivotal trials, while costs
were taken from standard sources including NHS Reference Costs, PSSRU, and the
British National Formulary. All costs were inflated to financial year 2009/2010, with
the perspective taken that of NHS Scotland. RESULTS: Using a 50 year (lifetime)
time horizon, with patients beginning treatment at age 62 (as seen in the clinical
trials), patients treated with Glusartel are estimated to cost £1799 more than those
treated with standard management (£6443 vs. £4645), but gain an additional 0.15 (2
d.p.) QALYs (9.45 vs. 9.31), generating an ICER of £12,402. Compared with currently
used glucosamine treatment, even conservatively assuming equal efficacy, Glusar-
tel produces a cost saving of £700, and is dominant in outcomes when the assump-
tion around treatment efficacy is relaxed. The model is sensitive to the time hori-
zon, utility in mild/moderate arthritis and data source for costs, with the main
driver being the efficacy of Glusartel in delaying severe arthritis. CONCLUSIONS:
From the perspective of NHS Scotland Glusartel is highly cost-effective compared
to standard of care, and cost saving compared to other glucosamine products. By
revising existing prescribing patterns, NHS Scotland could both improve patient
outcomes, and realise cost savings.
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OBJECTIVES: To review relevant Rheumatoid Arthritis (RA) economic models for
biologics; and identify potential model limitations. METHODS: Search targeted
economic evaluations of RA biologics since 2000 using Medline, EMBASE, and Co-
chrane databases. Articles were subjected to a two level review process before data
abstraction. RESULTS: Twenty-six economic evaluations were published assessing
costs and outcomes associated with RA biologics. Most models used a payer per-
spective. Two methotrexate (MTX)-naïve patient models were cost utility analyses
(CUA); one was a patient simulation model and one a decision analytic model. Of
seventeen models for disease modifying anti-rheumatic drug (DMARD)/MTX fail-
ure populations, sixteen were CUAs and one was a cost-effectiveness (CE) model
based on cost/ACR improvement achieved; model structures included patient level
simulation, Markov, and decision analytic models. Of seven models identified for
anti-TNF inhibitor failure populations, five were CUAs and two were CE models
where CE was defined by both cost/remission and cost of achieving low disease
activity (Disease Activity Score (DAS)28 3.2); six models employed a simulation
structure and one a Markov structure. Results varied widely across studies due to
heterogeneity in the time horizon, perspectives, year of costs and comparators.
Model Incremental cost effectiveness ratios (ICERs) ranged from $4,849 (2007$)
$47,157 (2007$) per QALY for MTX-naïve, $14,518 (1998$) $498,420 (2005$) per
QALY for DMARD/MTX failure, and $12,869 (2006$)$76,363 (2008$) per QALY for
TNF-failure. Key limitations included limited availability of treatment data over
long time horizons, and use of Health Assessment Questionnaire (HAQ) as primary
outcome and as determinant of utility. CONCLUSIONS: We recommend future
modeling efforts evaluate the use of direct utilities versus mapping; advantages of
CUA versus CE and simulation approach using patient level data; benefits of longer
time horizon; and inclusion of both health related quality of life assessment such
as HAQ and disease activity such as DAS-28 as model inputs.
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OBJECTIVES: Half of patients with systemic juvenile idiopathic arthritis (sJIA) will
eventually fail to non-steroidal anti-inflammatory drugs (NSAIDs) or corticoste-
roids. Tocilizumab (TCZ) is indicated for patients with refractory sJIA. We aimed to
determine the cost and the effectiveness of adding TCZ to conventional treatment
for sJIA in Mexico. METHODS: We designed two decision models to compare TCZ
versus placebo. In each model, two time horizons were analyzed: 12 weeks and one
year. Target population consists of patients (2-19 years) with active sJIA and inad-
equate response to NSAIDs and corticosteroids. The dosing scheme for TCZ was
based on body weight: 8 mg/kg for patients 30 kg and 12 mg/kg for patients 30
kg. The analysis was performed under the perspective of the public health care
system in Mexico. Tocilizumab acquisition cost, infusion fees and standard man-
agement of sJIA according to level of response were evaluated. Efficacy was defined
in terms of the American College of Rheumatology Pediatric response criteria. Re-
source use and unit costs were gathered from local sources; efficacy was derived
from two phase-3 clinical trials; increase in mortality and utility scores associated
with level of response was based on literature. All costs are expressed in 2011 euros
(€). RESULTS: A markedly higher proportion of patients achieved an ACRPedi70
response with TCZ in both children with the possibility of maintaining methotrex-
ate (71% vs. 8%) and in those without that alternative (75% vs. 13%). The incremen-
tal cost per achieving an ACRPedi70 response was around 2400€ in both models.
During base-case, the incremental cost per Quality-Adjusted Life Year (QALY)
gained with TCZ ranged from 10,636€ to 10,681€. The gross domestic product per
capita in Mexico during 2010 was estimated at 7048€. Results were robust to vari-
ation in all parameters. CONCLUSIONS: TCZ is a cost-effective option to treat sJIA
in Mexico.
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OBJECTIVES: Rheumatoid Arthritis (RA) leads to significant impact on manage-
ment costs and patient’s quality of life. In Brazil, costs associated to RA patient’s
care are 6.6-fold higher than general population, with greater resources consump-
tion. Biologic treatment after two disease-modifying antirheumatic drugs fail is an
alternative, but their high cost represents a challenge for decision makers. Cur-
rently, adalimumab, etanercept and infliximab are provided by the Brazilian public
healthcare system. This study aims to assess the cost per responder of etanercept
versus adalimumab and infliximab, for moderate to severe rheumatoid arthritis
treatment from a public payer perspective in Brazil. METHODS: A decision-tree
model was developed to simulate RA evolution after treatment with etanercept
(basecase treatment), adalimumab or infliximab as first-line therapies and their
associated costs over a 12-month time horizon. Therapy continuation or switch
was evaluated at week 24. Effectiveness measure was ACR70 response. Direct med-
ical costs included biologics, concomitant drugs, medical follow-up and adverse
events management. Clinical response was extracted from published literature,
while costs were collected from Brazilian public official databases. Probabilistic
sensitivity analyses were performed through Monte Carlo Simulation second-order
approach. RESULTS: In basecase analysis, 31.4%, 18.2% and 12.9% patients met
ACR70 response for etanercept, adalimumab and infliximab. Annual costs per
ACR70 responder were 147,147USD, 264,097USD and 327,632USD, respectively. Et-
anercept represented the least costly per ACR70 responder and the most effective
alternative in all comparisons: 116,950USD and 180,485USD less than adalimumab
and infliximab, respectively; 13.2% and 18.5% more patients met ACR70 response
regarding adalimumab and infliximab.CONCLUSIONS: Etanercept exhibited incre-
mental clinical effectiveness at a lower cost per ACR70 responders when compared
to adalimumab and infliximab, from the Brazilian public health care system.
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OBJECTIVES: Alendronate is subsidised in Australia for patients with a prior frac-
ture or those aged 70 with a bone mineral density (BMD) T-score of -3.0. The
objective of the analysis was to assess the cost-effectiveness of broadening access
to alendronate to individuals aged  70 with BMD T–score  –2.5. METHODS: A
cost-utility analysis was constructed using a microsimulation model of a Markov
process. The comparator was ‘no alendronate’ until such time that the individual
became eligible for treatment due to a fracture or to BMD T-score reaching -3. The
microsimulation transits patients through six health states of a Markov process
with the health states defined by treatment status (not eligible, on treatment,
discontinued treatment) and fracture status (with or without history of fracture).
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